Another reason for the increased AR-positivity rate in CTCs comparing to PT observed by Li et al., may be that all patients in this trial were pretreated with nonsteroidal aromatase inhibitors, and aromatase inhibitor treatment was previously shown to increase AR activity in BC [51]. Here, CYP19A1 is linked to breast cancer.